Peter Gebauer Sold 100 shares of LeMaitre Vascular Inc (NASDAQ:LMAT) in an Insider Trade

Share with your friends










Submit

Peter Gebauer Sold 100 shares of LeMaitre Vascular in an Insider Trade-Transactions

Peter Gebauer Insider Sell Transaction

Mr. Peter Gebauer, the current President – International OP at LeMaitre Vascular Inc (NASDAQ:LMAT) has a few days ago been linked with an open market sale of 100 shares of the public firm, valued at $14.4 per share. The amount of the trade was of $1,437 US Dollars. In the last month, he also unloaded 44,315 shares with a market value $619,081 USD. Peter Gebauer now owns 70,420 shares or 0.35 % of the company’s market capitalization.

Lemaitre Vascular Inc Stock Rating, Sentiment and Fundamentals

It is difficult to make conclusions about Lemaitre Vascular Inc’s future just from Peter Gebauer’s sale because in this filing, the insider also revealed option transactions. In the form, it was reported that Peter exercised options for 100 shares with average price 0.1020, worth 10. The seven professional analysts who cover Lemaitre Vascular Inc see earnings of $0.37 per share and 42.43 Price/Earnings ratio in 2015. This means a growth rate Year-Over-Year that is not more than 14.50%.

Rating & Sentiment
PsychSignal Social:SELL
Analysts Rating:BUY
Hedge Funds Sentiment:BUY
Stock Fundamentals
Earnings + FCF Trend:BUY
Sector/Industry Macro:BULLISH
Valuation Models:-
Technical Analysis
ST Trend:UP
MT Trend:UP
LT Trend:UP
OctaFinance Rating*:NEUTRAL

* Read How Our Stock Ratings System Works

In accordance with our live-tested stocks trend following model which is displayed below and considering the fact that Peter Gebauer has unloaded shares for such a massive amount, we rate this stock “NEUTRAL”. Lemaitre Vascular Inc’s share price is still trending upward from the last 200 days, during which it has increased 108.05 %.

Price Chart of Lemaitre Vascular NASDAQ:LMAT Stock

Peter Gebauer Sold 100 shares of LeMaitre Vascular in an Insider Trade-Stock-Price-Chart

Source: RightEdgeSystems, Yahoo Split & Dividend Adjusted Data and OctaFinance Interpretations

The consensus amongst the famous speculators has always been that a combination of fundamental and technical analysis allows for the best returns, epitomized by John Burbank. This doesn’t look to be the case with this company. The date was 20-11-2015 when Peter filled the sale, and it was disclosed in a document with the SEC, at your disposal on this website.

Hedge Funds Ownership

Data gathered from 13F SEC filings, reveal that 71 hedge funds and institutional investors owned shares of Lemaitre Vascular Inc. The tracked institutional players have historically had a high interest in this company, and that was also the case in Q2 2015. The institutional ownership was 49.16 % of the stock’s outstanding shares. Its up 6.58 % from previous quarter. These stock owners increased the total shares they own by 550,183 to 8.91 million this quarter. There were 8 funds that closed their positions and 14 that reduced them. A total of 31 funds opened new positions in Lemaitre Vascular Inc and 16 increased their holdings.

This stock is held by two funds in their Top 10 stock positions. They are: Perkins Capital Management Inc, Awm Investment Company Inc..

HEDGE-FUNDS-LIST-DATABASE-FREE

Perkins Capital Management Inc is the most positive institutional investor on Lemaitre Vascular Inc, with ownership of 180,805 shares as of Q2 2015 for 1.92% of the fund’s portfolio. Awm Investment Company Inc. is another positive investment manager possessing 1.33 million shares of the company or 2.28% of their stocks portfolio. The stock is also 1.51% of the fund’s AUM. Further The Wyoming-based fund Cannell Capital Llc have 3.01% of their stock portfolio invested in the company’s market cap for 763,265 shares. Longwood Capital Partners Llc disclosed it had acquired a stake worth 1.86% of the fund’s stock portfolio in Lemaitre Vascular Inc. First Light Asset Management Llc is also confident in the company, with ownership of 320,768 shares or 1.82% of their stock portfolio.

LeMaitre Vascular NASDAQ:LMAT Company Profile

LeMaitre Vascular, Inc. is a provider of medical devices for the treatment of peripheral vascular disease. The Company and its subsidiaries develop, manufacture and market medical devices and implants used primarily in the field of vascular surgery. The Company’s product lines include valvulotomes, balloon catheters, carotid shunts, biologic patches, biologic grafts, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, angioscopes and powered phlebectomy devices. The Company develops, manufactures and markets vascular devices to address the needs of vascular surgeons. Its portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, VascuTape Radiopaque Tape and the XenoSure biologic patch.

Company Website: LeMaitre Vascular

Lemaitre Vascular Inc was founded in Delaware on 1998-06-15. Lemaitre Vascular Inc has 325 employees. As of writing its market worth is: $285.69 million and it has 19.85 million outstanding shares. Now the company has 60.65% shareholders and the institutional ownership stands at 60.65%. The stock closed at $15.77 yesterday and it had average 2 days volume of 52827 shares. It is up from the 30 days average shares volume of 34558. Lemaitre Vascular Inc has a 250 days low of $7.00 and a 250 days high of $15.99. The current price is above the 200 days SMA. Lemaitre Vascular Inc last issued its quarterly earnings data on 10/27/2015. The company reported 0.11 EPS for the quarter, above the consensus estimate of 0.08 by 0.03. The company had a revenue of 19.03 million for 9/30/2015 and 19.90 million for 6/30/2015. Therefore, the revenue was -872,000 down.

* Represents shares acquired upon exercise of options by the Reporting Person – as reported in Table II.

* This option is fully vested and exercisable.

* This stock option was originally reported on Form 3 as having an expiration date of June 2 – 2007 – but does not in fact have an expiration date. Because an expiration date is required to be reported – the originally reported expiration date is included for the sake of consistency.

LeMaitre Vascular - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.